✉ Email this page to a colleague
« Back to Dashboard
HKI-357 is an investigational drug.
There have been 22 clinical trials for HKI-357. The most recent clinical trial was a Phase 3 trial, which was initiated on July 9th 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Puma Biotechnology, Inc., Wyeth is now a wholly owned subsidiary of Pfizer, and NSABP Foundation Inc.
Recent Clinical Trials for HKI-357
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Puma Biotechnology, Inc.||Phase 2|
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Translational Breast Cancer Research Consortium||Phase 2|
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Dana-Farber Cancer Institute||Phase 2|